Dr. Matthew Zibelman, MD
Claim this profileFox Chase Cancer Center
Area of expertise
Renal Cell Carcinoma
Matthew Zibelman, MD has run 3 trials for Renal Cell Carcinoma. Some of their research focus areas include:
Kidney Cancer
Matthew Zibelman, MD has run 3 trials for Kidney Cancer. Some of their research focus areas include:
Affiliated Hospitals
Fox Chase Cancer Center
Clinical Trials Matthew Zibelman, MD is currently running
EU101
for Solid Cancers
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Recruiting
1 award
Phase 1 & 2
10 criteria
Cabozantinib
for Kidney Cancer
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
Recruiting
3 awards
Phase 2
10 criteria
More about Matthew Zibelman, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Matthew Zibelman, MD has experience with
- Nivolumab
- Cabozantinib
- Axitinib
- VTP-850
- EU101
- BT7480
Breakdown of trials Matthew Zibelman, MD has run
Renal Cell Carcinoma
Kidney Cancer
Prostate Cancer
Neuroendocrine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Zibelman, MD specialize in?
Matthew Zibelman, MD focuses on Renal Cell Carcinoma and Kidney Cancer. In particular, much of their work with Renal Cell Carcinoma has involved Stage IV patients, or patients who are EGFR negative.
Is Matthew Zibelman, MD currently recruiting for clinical trials?
Yes, Matthew Zibelman, MD is currently recruiting for 2 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Matthew Zibelman, MD has studied deeply?
Yes, Matthew Zibelman, MD has studied treatments such as Nivolumab, Cabozantinib, Axitinib.
What is the best way to schedule an appointment with Matthew Zibelman, MD?
Apply for one of the trials that Matthew Zibelman, MD is conducting.
What is the office address of Matthew Zibelman, MD?
The office of Matthew Zibelman, MD is located at: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 United States. This is the address for their practice at the Fox Chase Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.